• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Saliva-Omics in Plasma Cell Disorders -- Proof of Concept and Potential As a Non-Invasive Tool for Monitoring Disease Burden and MRD Status
This study provides proof of concept that a range of biologically significant proteins of interest can be reliably detected in the saliva of MM and MGUS patients. The observation of differential expression of FABP5 between MGUS and MM identified these as candidate proteins relevant to malignant transformation of MGUS to symptomatic MM. The demonstration of decreased abundance of FABP5 after achieving remission indicates a correlation with tumour burden. This opens the opportunity to explore candidate salivary biomarkers for use in the clinic for disease monitoring and Minimal Residual Disease (MRD) assessment.DisclosuresNo...
Source: Blood - November 21, 2018 Category: Hematology Authors: Tierney, C., Bazou, D., Le, G., Dowling, P., O'Gorman, P. Tags: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II Source Type: research

Treatment Failure in Patients Receiving Direct Oral Anticoagulants: Clinical Management and Outcomes from a Single-Center Review of 59 Consecutive Patients
In this study, we sought to characterise DOAC treatment failures in our institution, and to rationalise the subsequent anticoagulation strategies in this setting. All VTE patients starting a DOAC at our centre are followed in a consultant-led clinic. Cases of suspected treatment failure are also referred from other specialities and primary care. Between September 2014 and May 2018, we identified 59 consecutive patients (male/female: 34/25) in whom a DOAC treatment failure was diagnosed, including non-resolution of the presenting complaint, and recurrence of or a new thrombotic event. Patient mean age at DOAC initiation was...
Source: Blood - November 21, 2018 Category: Hematology Authors: McIlroy, G., Smith, N., Lokare, A., Beale, K., Kartsios, C. Tags: 332. Antithrombotic Therapy Source Type: research

Saliva-omics in Plasma Cell Disorders-proof of concept and potential as a non-invasive tool for monitoring disease burden and MRD status.
Salivaomics has exciting potential for the diagnosis and monitoring of malignancy, evidence of which has been reported in oral cancer, head and neck malignancies and ovarian cancer. It has been observed that approximately 40% of cancer, stroke and cardiovascular disease biomarkers are present in whole saliva. Salivaomics has become an area of great interest in disease diagnosis over the last number of years, following the footsteps of the other "omics ” based diagnostic tools. Saliva is a fast, inexpensive and non-invasive method of sample collection therefore it might be considered as the biofluid of choice for the diag...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: Ciara Tierney, Despina Bazou, Giao Le, Paul Dowling, Peter O'Gorman Source Type: research

Is there a role for low-dose DOACs as prophylaxis?
Authors: Cohen AT, Hunt BJ Abstract The direct oral anticoagulants (DOACs) have transformed the management of thrombotic disorders. Large clinical trials have demonstrated that DOACs can replace vitamin K antagonists (VKAs) in the 2 existing major indications for anticoagulation: the prevention of stroke in atrial fibrillation and the acute treatment and secondary prevention of venous thromboembolism (VTE); this literature is widely known. In this article, we will concentrate on the less well-discussed benefits of the use of DOACs-using low doses as primary and secondary prophylaxis in both venous and arterial thro...
Source: Hematology ASH Education Program - December 7, 2019 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care
In this study, we assessed the impact of interacting medication and pharmacogenetic variation to better explain apixaban concentration differences among 358 Caucasian AF patients. Genotyping (ABCG2,ABCB1,CYP3A4*22,CYP3A5*3) was performed by TaqMan assays, and apixaban quantified by mass spectrometry. The typical patient was on average 77.2  years old, 85.5 kg, and had a serum creatinine of 103.1 µmol/L. Concomitant amiodarone, an antiarrhythmic agent and moderate CYP3A/ABCB1 inhibitor, the impaired-function variantABCG2 c.421C  >  A, and sex predicted higher apixaban concentrations when controlling for age, weig...
Source: Journal of Thrombosis and Thrombolysis - January 18, 2020 Category: Hematology Source Type: research

Novel Bleeding Risk Score for Patients with Atrial Fibrillation on Oral Anticoagulants, including Direct Oral Anticoagulants.
CONCLUSION: In this prospective cohort study of AF patients and predominantly DOAC users, we successfully derived a bleeding risk prediction model with good calibration and discrimination. PMID: 33501722 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 27, 2021 Category: Hematology Authors: Adam L, Feller M, Syrogiannouli L, Del-Giovane C, Donzé J, Baumgartner C, Segna D, Floriani C, Roten L, Fischer U, Aeschbacher S, Moschovitis G, Schläpfer J, Shah D, Amman P, Kobza R, Schwenkglenks M, Kühne M, Bonati L, Beer J, Osswald S, Conen D, Auje Tags: J Thromb Haemost Source Type: research

OC-12: Stroke and risk of cancer: a Danish population-based cohort study
Source: Thrombosis Research - May 1, 2022 Category: Hematology Authors: N. Skajaa, K. Veres, F.S. Troelsen, J.D. Petersen, K. Adelborg, H.T. S ørensen Tags: Oral Communications Source Type: research

Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: The Last 10 Years
Semin Thromb Hemost DOI: 10.1055/s-0043-1769013Current guideline recommendations for primary prophylaxis of venous thromboembolism (VTE) are based on randomized clinical trials that usually exclude subjects at a potentially high risk of bleeding complications. For this reason, no specific guideline is available for thromboprophylaxis in hospitalized patients with thrombocytopenia and/or platelet dysfunction. However, except in patients with absolute contraindications to anticoagulant drugs, antithrombotic prophylaxis should always be considered, for example, in hospitalized cancer patients with thrombocytopenia, especially...
Source: Seminars in Thrombosis and Hemostasis - May 18, 2023 Category: Hematology Authors: Tufano, Antonella Brenner, Benjamin Tags: Review Article Source Type: research

Pages: 1  2